ReviewExpert review of neurotherapeutics2013
Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies.
Review in Expert review of neurotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Uncovering a feedback loop in glioblastoma that reinforces stemness and immunosuppression.The Journal of clinical investigation · 2026Article
- Defined pulsed electro-magnetic field exposure suppresses stemness and potentiates temozolomide-induced apoptosis in glioblastoma cells.Scientific reports · 2026Article
- Review
- Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.Therapeutic delivery · 2025Review
- Article
- Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets.Cells · 2024Review
- Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments.World journal of stem cells · 2024Article
- Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers.International journal of molecular sciences · 2023Review
- Cellular senescence in glioma.Journal of neuro-oncology · 2023Review
- METTL3-mediated m6A modification of LINC00839 maintains glioma stem cells and radiation resistance by activating Wnt/β-catenin signaling.Cell death & disease · 2023Article
- αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform.Biotechnology and bioengineering · 2023Article
- Article
- The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition.Molecular cancer research : MCR · 2022Article
- Disruption of β-catenin-mediated negative feedback reinforces cAMP-induced neuronal differentiation in glioma stem cells.Cell death & disease · 2022Article
- Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress.Molecular cancer research : MCR · 2021Article
- Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021Article
- Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide.Cancers · 2021Article
- Targeting Glioma Stem Cells.Neurosurgery clinics of North America · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Glioblastoma multiforme is one of the most aggressive brain tumors in adults. Despite the use of the best available multimodal therapeutic approaches, the prognosis remains dismal. The identification of glioma stem cells (GSCs) has offered new hope to affected patients, since it could explain, in part, the highly heterogeneous nature of this tumor and its chemo- and radio-resistance. Although still in its infancy, GSC research has unveiled many of its complexities and the theory itself remains controversial. GSC phenotype can significantly vary between patients and a single tumor may present several distinct GSCs. New therapeutic solutions that effectively target this population are of utmost importance, since they may be able to decrease neoplastic recurrence and improve patient survival. Here, we discuss the mechanisms by which GSCs lead to glioma relapse, the main controversies in this field and the most recent treatments that could successfully target this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.